Last CNY19.68 CNY
Change Today +0.33 / 1.71%
Volume 1.5M
300147 On Other Exchanges
As of 3:00 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by XIANGXUE PHARMACEUTICAL CO-A (300147) in the last 6 months

Announced 07/23/14
50.00M for Fusong Changbaishan Ginseng Market Investment & Development Co., Ltd.
Private Placement

Fusong Changbaishan Ginseng Market Investment & Development Co., Ltd. announced that it will receive CNY 50,000,000 in an equity round of funding from new investor, Xiangxue Pharmaceutical Co., Ltd. on July 23, 2014. As part of the transaction, the company will transfer CNY 3,333,300 to its registered capital and the balance of CNY 46,666,700 to its capital reserve. On closing, the registered capital of the company will increase to CNY 13,333,300. On completion of the ...
Read More

300147's price was unchanged after the transaction was announced on 07/23/14.
Investor / Buyer
Xiangxue Pharmaceutical Co., Ltd.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300147:CH CNY19.68 CNY +0.33

300147 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300147.
View Industry Companies

Industry Analysis


Industry Average

Valuation 300147 Industry Range
Price/Earnings 52.3x
Price/Sales 3.4x
Price/Book 3.2x
Price/Cash Flow 52.6x
TEV/Sales 5.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XIANGXUE PHARMACEUTICAL CO-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at